SolasCure, a biotechnology company that is dedicated to working towards filling the current market gap in debridement – the removal of necrotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR).

The HFX iq, a personalised spinal cord stimulation (SCS) system developed by Nevro that leverages artificial intelligence technology to manage chronic pain, has received CE mark certification in Europe.

Pharmarole.com

Page 13 – improving the patient experience: insights from uganda, the uk and us

Welcome to the final edition of 2024: Pharmafocus December.

Salarysurvey.pharmarole.com

Earlier in November, the Chalmers University of Technology in Sweden published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics.

Msea.pharmatimes.com

Biotech company Cytomos has announced this month that it has raised £5m to scale up the production of its unique cell analysis technology.

Leading global healthcare company Novo Nordisk, who is a top contender for the industry's first $1trn valuation after the launch of its groundbreaking diabetes drug Ozempic in 2017, is set to introduce a promising new weight-loss treatment called CagriSema.

Advance Tests, committed to enhancing diagnostic accessibility and advancing early disease detection, announced the exclusive UK launch of LucentAD complete.

French biotech AdipoPharma has announced that it has secured funding for a clinical trial into its type 2 diabetes therapeutic, PATAS.

Global biopharma company GSK has announced positive phase 3 results for its cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) treatment, linerixibat, which is currently being studied in the GLISTEN trial.

UK-based Barinthus Biotherapeutics has announced data from its ongoing phase 2b HBV003 clinical trial, which was presented at the American Association for the Study of Liver Diseases (AASLD) Meeting 2024.

Puma Biotechnology has announced the initiation of its alisertib in cancer (ALISCATM-Breast1) phase 2 trial of alisertib in combination with endocrine therapy. Based on the outcomes of the trial, the company anticipates to meet with the US Food and Drug Administration (FDA) regarding an approval pathway.

BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of the most common type of bladder cancer, metastatic or unresectable urothelial carcinoma.

Approval of an updated version of the Nuvaxovid COVID-19 vaccine, developed by Novavax, has been granted by the Medicines and Healthcare products Regulatory Agency (MHRA), to target the omicron JN.1 COVID-19 subvariant.

Theramex, a dedicated women’s health company, has announced that the Scottish Medicines Consortium (SMC) has recommended YSELTY (linzagolix) for the treatment of moderate or severe symptoms of uterine fibroids (UFs) in adult women of reproductive age.

Earlier in November, Johnson & Johnson Innovative Medicine have applied to the US Food and Drug Agency (FDA) and the European Medicines Agency (EMA) for the approval of a new indication for DARZALEX FASPRO (daratumumab and hyluronidase-fihj).

Sartorius Stedim Biotech, a global biotechnology company focused on accelerating scientific breakthroughs based in Germany, has announced the opening of its new innovation facility in Massachusetts, US.

Aravax, a biotechnology company specialising in next-generation immunotherapies, has launched a UK subsidiary at the Oxford Science Park.

Global leader in R&D sample stability and biorepository storage Astoriom has announced the acquisition of both MTS Cryo stores and Cool Repair Scientific UK (both Nottingham, UK).

Infrareal holding has announced that it has entered into a corresponding transfer agreement with Takeda to acquire the 24-hectare site in Orth, Lower Austria – subject to merger control approval from Austrian regulators.

Www.samedanltd.com

Improving patient experience is increasingly recognised as essential to enhancing healthcare quality, satisfaction and health outcomes across the globe. By understanding the unique challenges and opportunities in different regions, healthcare systems can develop more effective, patient-centred care models.

Exevir Bio, a biotech company focused on developing heavy chain-only antibodies to target highly conserved epitopes for broad-spectrum protection against infectious diseases, has announced the appointment of Michael Garrett as its new CEO.

Following the stepping down of the previous chair, Gerd Zettlmeissl, MinervaX has appointed Veronica Gambillara Fonck to lead the board of directors.

Biosynth – known for supplying the life sciences industry with critical raw materials and services – has announced that Matt Gunnison has been appointed as its new CEO and Kieran Murphy has been appointed as chairman.

Explore more about Pharmafocus, including previous issues which cover some of the most interesting news in the pharmaceutical sphere.

1. Maggot therapy is the use of green or bluebottle fly maggots for the removal of necrotic or infected tissue (debridement). The maggots can also remove devitalised cells that have accumulated in the wound (sloughy tissue).1

Interphex.com

Pharmatimes.com